Rheumatology: Current Research
Open Access

The First Reported Case of Trichosporon asahii in Systemic Lupus Erythematosus (SLE) from Riyadh, Saudi Arabia

Albaadani A^1*, Kallam K¹ and Albarrag A^{2 *}Correspondence: Albaadani A, Department of Medicine, Prince Sultan Military Medical City, Riyadh, Saudi Arabia, Tel: +966 5444 72 789, Email:

Author info »

Background

Trichosporon asahii is yeast originating from the Basidiomycetes class. It is considered a life-threatening opportunistic pathogen, most prominently for neutropenic and immunocompromised patients [1]. Invasive infections have also been documented in immunocompetent patients as well those in post-surgery [2-4]. Trichosporon spp is widely present in nature and isolated from soil and water as well as colonising the oral, skin, and gastrointestinal tract of normal human flora [1]. Amphotercine B has exhibited limited in vitro efficacy against the Trichosporon [5]. In vitro data has suggested that voriconazole is the antifungal agent of choice for a disseminated Trichosporonosis [6,7].

Case Presentation

A 26-year-old female diagnosed as SLE complicated with lupus nephritis for 7 years (for which she was on 10 mg of prednisone), presented to the emergency department with a history of fever and abdominal pain for 12 days. She reported fever of more than 38.2 degrees together with pain. There was no history of diarrhea, skin rashes, joint pains, or any neurological symptoms. She sought medical advice in a private hospital where she was found to be pancytopenic. The patient underwent a CT scan of the abdomen and pelvis which showed intramural thickening in cecum with mild free fluid in the right iliac fossa. She was treated with broad spectrum antibiotics and, owing to low complements levels suggestive of active lupus, pulse steroids were administered. The patient showed slight clinical improvement and was discharged from the hospital. Two days later, the patient presented to our hospital with severe abdominal pain and fever. A clinical examination revealed a temperature of 36.1 degrees, a pulse of 114/min, blood pressure of 115/55, and a respiratory rate of 16/min with normal O2saturation at room air. She reported a diffusely tender abdomen. Her blood counts on admission were within normal limits. A CT scan of the abdomen showed hyper enhancement of the sigmoid colon with mild thickening and submucosal edema with an adjacent focal collection measuring 3.3×2.7 cm abutting its wall. There was extensive free air, primarily around the sigmoid colon, descending the colon and splenic flexure, as well as beneath the anterior abdominal wall. The patient was immediately taken for exploratory laparotomy and resection of the perforated sigmoid colon, following which she was transferred to the Intensive Care Unit (ICU). The following day she was extubated with a Glasgow Coma Scale (GCS) of 15/15, representing stable haemodynamic status. On the second day, the postoperative patient developed tachycardia with a pulse rate of 120 and her hemoglobin fell from 9.8-3 gms/dl. There was evidence of coffee brown aspirate from the nasogastric tube plus signs of active bleeding in the colostomy bag.

An endoscopy showed diffuse ulceration and active bleeding from the mid and lower oesophagus. Left gastric artery embolisation was present and she was transfused with 3 pints of packed RBCs. On the third day, the treating physician noticed a blackish encrusted rash in her nasal and oral areas, which raised the possibility of invasive fungal infection in an immunocompromised patient, and she was referred to the infectious diseases specialty for further assessment. Based on the overall clinical context of the patient’s condition, she was started on liposomal amphotericin 5 mg/kg to cover the high possibility of invasive fungal infections, namely Mucor mycosis. This usually tends to manifest as profuse bleeding due to severe angioinvasion, which is characteristic in a high risk group of patients.

On day four, the post-surgery patient became tachypnoeic and desaturated. She was intubated with Fio2 of 40% and there were blood tinged secretions from the endotracheal tube. Her renal function had begun to rise with a serum creatinine of 290 micromol/L. She was then started on two antibiotics, meropenem and teicoplanin. The patient underwent a bronchoscopy which revealed an extensive bilateral alveolar haemorrhage. The rheumatology team started her on IVIG and plasma pheresis. Bronchoalveolar lavage grew pansensitive Pseudomonas Aeruginosa and was negative for any fungal or mycobacterial organisms.

The histopathology of an intraoperative sigmoid biopsy reported invasive fungal infection but was in-conclusive (Figure 1). A culture of the biopsy was not sent. Formalin-Fixed Paraffin- Embedded (FFPE) tissue was sent to a reference clinical mycology laboratory for molecular diagnosis and identification using panfungal PCR and sequencing. The PCR products were sequenced and species identification was achieved using the Basic Local Alignment Search Tool (BLAST). The sequence results showed a 100% sequence similarity to Trichosporon asahii.

Figure 1. Histopathology of sigmoid biopsy.

The patient continued to experience active bleeding from her colostomy. An ACT scan showed mucosal thickening of the sinuses and ENT was contacted for possible debridement and biopsy. However, they could not proceed as the platelets had fallen precipitously and were refractory to any treatment and transfusions. The patient’s renal profile was deteriorating daily and nephrology became involved to provide replacement therapy. Ten days later the patient started becoming hypotensive, requiring ionotropic support and hypothermic. Her blood culture grew Extensive Drug Resistant (XDR) Klebsiella. The patient was started on ceftazidime avibactam to which the organism was sensitive. All her central lines were changed and she was able to clear her bacteremia and her vital signs improved. The result of a rectal swab culture as part of ICU surveillance for Multi-Drug Resistance (MDR) showed fungal growth consistent with Trichosporon spp. This was sensitive to the ambisome the patient was receiving. The patient went through several events of bleeding secondary to severe pancytopenia for which she received blood products, IVIG, and plasma exchanges.

Three weeks later the Quinton line blood culture grew yeast, for which caspofungin was added to liposomal amphotericin.

However, the patient died due to intractable sepsis, bleeding, and a flare up of SLE six weeks after her admission into hospital.

The yeast isolated from the blood culture was identified as a Trichosporon species using API 20C AUX (bioM ́erieux, Mercy l’Etoile, France), which was sensitive only to voriconazole and flucytosine using Sensititre YeastOne^® (Thermo Scientific) (Figures 2 and 3).

Figure 2. Blood culture: Yeast growth in Sabouraud dextrose agar.

Figure 3. Blood culture: Yeast growth in CHROMagar.

Discussion

SLE is an autoimmune disease that in most cases requires a potent immunosuppressant treatment, including a high dose of corticosteroids. These play a major deregulatory role in immune status leading to varying vulnerability to several types of fungal infections with substantial mortality and morbidity [8]. The most common corticosteroids associated with invasive fungal infections in SLE are Aspergillus, Candida and PCP [9-11]. Over the last few decades a non-Candida yeast infection known as Trichosporon species has emerged in immunocompromised hosts, mostly in hematological malignancies where it is considered the second leading cause of fungaemia after candida species [1]. Trichosporon is basidiomycetous yeast that consists of septate hyphae, arthroconidia and pseudohyphae. It exhibits the same mycological characteristics as the Geotrichum species as both can produce arthroconidia and true hyphae from cultures. However, Geotrichum results in a negative urease test, unlike the Trichosporon species [5]. Tichosporon can be associated with superficial skin and subcutaneous infections such as white Piedra or it can progress to a devastating invasive infection in immunocompromised hosts, such as cancer, AIDS, and prolonged neutropenia, and require the use of corticosteroids [1]. The majority of cases of Trichosporonosis have been North American (33.9%), followed by cases in Europe (27.6%) and Asia (23.3%) [5], disseminated cases of Trichosporon have been reported in immunocompetent patients from China, India, and the USA [2-4]. Invasive Trichosporon cases from Saudi Arabia are rare. However, Alhedaithy et al. reported up to 3.2% noncandida related fungemia secondary to Trichosporon begeli [12]. There have been two reports of successful treatment with amphotericin of cavitating pneumonia secondary to Trichosporon begeli in acute myeloid leukemia [13,14].

Herein, we are reporting a rare presentation of invasive fungal infection secondary to Trichosporon spp. in a young, critically ill female with advanced SLE. She had presented with an acute abdomen that necessitated sigmoid resection with a colostomy. This presentation was initially attributed to vasculitis related bowel ischemia. However, the histopathological result revealed elements of invasive fungal infection, although this was inconclusive. Based on the clinical presentation, mucormycosis was considered owing to its angioinvasion pathogenicity which results in severe intestinal bleeding, as was the case in our patient. Ambisome had been started on day one of the clinical suspension. Thereafter, PCR had shown evidence of Trichosporon asahii. Nevertheless, the patient was continued on ambisome which treats mucormycosis and exhibits variable in vitro susceptibility to Trichosporon as a few reported cases have responded to amphotericin B monotherapy or in combination with flucytosin [3]. During the surveillance of multi drug resistant organisms (MDRO) in the ICU, the patient was found to have Trichosporon asahii, detected from a rectal swab and from blood culture. This was sensitive to voriconazole, fluconazole, itraconazole, amphotericin B and resistant to all echinocandines. Triazoles exhibit better in vitro and in vivo antifungal activities against Trichosporon spp. than amphotericin B [5]. Owing to excessive bleeding, oral voriconazole could not be started nor was an intravascular route used as the patient suffering acute kidney injury [15]. Therefore, the patient was kept on ambisome combination therapy with caspofungin pending a full yeast identification result which was verified after the patient’s death. Notably, a combination of echinocandin with amphotericin B or azoles have demonstrated some in vitro and in vivo synergistic antifungal effects [16-19].

To the best of our knowledge, a Trichosporon invasive infection in SLE has been reported in only one patient from Thailand, who was suffering from fungaemia secondary to central line [18]. Our patient is likely to be the second case. The uncertainty of the diagnosis due to the initial histology in our patient addresses another highly critical IFI, which is that mucormycosis, particularly with a correlating clinical presentation, may have forfeited the opportunity to offer the best available therapy earlier in the course for disseminated Trichosporon. The definitive microbiological isolates were only identified postmortem. The overall prognosis of Trichosporonosis is very poor, even with appropriate antifungal treatment, which is usually voriconazole or ambisome in combination with flucytosine or fluconazole. Mortality varies from 60% to 80%, especially in the presence of neutropenia [20].

Conclusion

Trichosporon is an opportunistic fungal infection that requires a high index of clinical suspicion. Molecular diagnosis is a rapid and highly sensitive reliable diagnostic tool that can play a crucial role in speeding up the diagnosis. Treatment should be offered promptly and, based in vitro and retrospective clinical data should consist of an appropriate anti-fungal therapy such as voriconazole.

Outweighing the benefits and risks of providing voriconazole in the event of acute renal impairment is the substantial impact of the treatment on a disease with extremely high mortality.

Conflict of Interest

We declare no conflict of interest for the authors

References

1. Miceli MH, Díaz JA, Lee SA. Emerging opportunistic yeast infections. Lancet Infect Dis. 2011;11(2):142-151.
2. Devi KM, Mate P, Singh L, Devi KR, Devi KS. Disseminated infection with Trichosporon asahii in an immunocompetent patient: A rare case report. J Med Soc. 2015;29(3):174-176.
3. Yang R, Ao J, Wang W, Song K, Li R, Wang D. Disseminated Trichosporonosis in China. Mycoses. 2003;46(11-12):519-523.
4. Mada PK, Ayoade F, Li A, Todd J. Trichosporon asahii septic thrombophlebitis following lower extremity amputation in an immunocompetent host. BMJ Case Rep. 2018;1:(8)222.
5. Colombo AL, Padovan ACB, Chaves GM. Current knowledge of Trichosporon spp. and Trichosporonosis. Clin Microbiol Rev. 2011; 24(4):682-700.
6. Asada N, Uryu H, Koseki M, Takeuchi M, Komatsu M, Matsue K. Successful treatment of breakthrough Trichosporon asahii fungemia with voriconazole in a patient with acute myeloid leukemia. Clin Infect Dis. 2006;43(4):e39-41.
7. Matsue K, Uryu H, Koseki M, Asada N, Takeuchi M. Breakthrough Trichosporonosis in patients with hematologic malignancies receiving micafungin. Clin Infect Dis. 2006;42(6):753-757.
8. Lionakis MS, Kontoyiannis DP. Glucocorticoids and invasive fungal infections. Lancet. 2003; 362(9398):1828-1838.  
9. Calich I, Ma M, Lichtenstein A. Causes of death in patients with Systemic Lupus Erythematosus in são paulo, brazil: A study of 113 autopsies. Arch Intern Med. 2001;161(12):1557.
10. Wang LR, Barber CE, Johnson AS, Barnabe C. Invasive fungal disease in Systemic Lupus Erythematosus: A systematic review of disease characteristics, risk factors, and prognosis. Semin Arthritis Rheum. 2014; 44(3):325-330.
11. Weng CT, Liu MF, Weng MY, Lee NY, Wang MC, Lin WC, et al. Pneumocystis jirovecii pneumonia in Systemic Lupus Erythematosus from Southern Taiwan. J Clin Rheumatol. 2013;19(5):252-258.
12. Al-Hedaithy SSA. The yeast species causing fungemia at a university hospital in Riyadh, Saudi Arabia, during a 10-year period. Mycoses. 2003;46(8):293-298.
13. Santhosh-Kumar CR, Al-Hedaithy SSA, El-Saghir NS, Ajarim DSS. Cavitating pneumonia due to Trichosporon beigelii in a patient with acute myeloid leukaemia. J Infect. 1989;19(1):67-68.
14. Qadri SM, Ellis ME. Localized pulmonary disease due to Trichosporon beigelii. J Natl Med Assoc. 1992;84(5):449-452.
15. Wang F. Voriconazole therapy: Associated acute kidney injury. African J Microbiol Res. 2011;5(25):4359-4362.
16. Bassetti M, Bisio F, Di Biagio A, Pierri I, Balocco M, Soro O, et al. Trichosporon asahii infection treated with caspofungin combined with liposomal amphotericin B. J Antimicrob Chemother. 2004;1;54(2):575-577.
17. Serena C, Pastor FJ, Gilgado F, Mayayo E, Guarro J. Efficacy of micafungin in combination with other drugs in a murine model of disseminated Trichosporonosis. Antimicrob Agents Chemother. 2005; 49(2):497-502.
18. Issarachaikul R, Lertwannawit O, Detporntewan P, Uaprasert N, Plongla R, Shuangshoti S, et al. Case series catheter-related bloodstream infections caused by Trichosporon species. Southeast Asian J Trop Med Public Health. 2014;45(2):421-419.
19. Pfaller MA, Diekema DJ. Rare and emerging opportunistic fungal pathogens: Concern for resistance beyond candida albicans and aspergillus fumigatus. J Clin Microbiol. 2004;42(10):4419-4431.
20. Kozel TR, Wickes B. Fungal diagnostics. Cold Spring Harb Perspect Med. 2014;4(4): a019299.